Updates on Crispr for treatment of Genetic ALS / FTD From Arbor Biotechnologies

Arbor Biotechnologies, a gene editing pharmaceutical company, recently announced 3 potential treatments for Genetic ALS / FTD to move towards clinical trials. See the press release announcing this here https://arbor.bio/arbor-biotechnologies-nominates-three-gene-editing-development-candidates-for-als-with-potential-to-address-up-to-97-of-people-living-with-the-disease/ . Two leaders of the organization Mat Pletcher, Ph.D. and Albert Misko, Ph.D., MD will present on these candidates and general background on gene editing for adult onset conditions.